27.05.2016 04:41:59
|
WSJ : Valeant Rejected Joint Takeover Approach From Takeda, TPG
(RTTNews) - Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) received a joint takeover approach this spring from Japan's Takeda Pharmaceutical Co. and private-equity firm TPG that the beleaguered drugmaker rejected, the Wall Street Journal reported citing people familiar with the matter.
The approach came a month or two ago, before Valeant named Joseph Papa as its new chief executive, and didn't include a firm price, the report said, adding that there are no current talks. The board is seeking to give Papa, who was hired in late April, time to chart a course for the company.
At the time of the advance, Valeant was buffeted by an accounting scandal and questions over its debt load, and was seeking a replacement for Michael Pearson as chief executive.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Valeant Pharmaceuticals Internationalmehr Nachrichten
Keine Nachrichten verfügbar. |